VBL Therapeutics Prices 2.5 Million Ordinary Share Offering
TEL AVIV, Israel, Nov. 17, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced the pricing of …